Predictable study metrics are facilitated by pre-emptive trial management:

As a worldwide clinical trials client you benefit from rigorous feasibility assessments and planning; insights gleaned from applied clinical research in comparable trials; and tailored solutions to anticipated challenges built into your operational plan.

Global access to oncology investigators and patients is unparalleled:

With an established reputation for operational excellence we provide access to qualified sites in locations as diverse as Russia, Eastern Europe, the Middle East and North Africa, where study competition is low or absent and investigator acumen recognized. Our effective site management assures predictable study metrics and milestones.

Delivering innovative science and facilitating better patient care is central to our mission:

Methodological rigor is a hallmark of our team’s professional experience from drug discovery (irreversible tyrosine kinase inhibitor) through clinical development.Our commitment to both site and patient centered clinical research and trial methodology means that processes  are designed to enable the clinical characterization of innovative pharmacology by delivering consistently reliable data in the context of impeccable clinical care.  From translational medicine (e.g. gene expression profiling) to “first patient-in” for prototypical dose ranging trials, our pre-emptive trial management minimizes protocol amendments and assures execution to milestones and timelines

Objectives beyond therapeutic novelty are what make us leaders: 

An increasingly complex healthcare environment demands competition on value as well as innovation in oncology therapies.  Our partnership with key opinion leaders at the Thomas Jefferson University School of Population Health enables creation of research programs that resonate with multiple, country-specific stakeholders; ensuring regulatory success matches successful commercialization. 

Phase I-IV experience:

Solid Tumor Malignancies

• Breast
• Brain
• Cervix uteri
• Colon
• Lung
• Ovary
• Pancreas
• Prostate
• Kidney
• Small Intestine
• Stomach
• Thyroid
  

Hematological Malignancies

• Multiple myeloma and malignant plasma cell neoplasms
• Myelodysplastic syndromes
• Non-Hodgkin’s lymphoma
• Chronic Lymphocytic Leukemiav
• Chronic Myelogenous Leukemia Hormone therapy

Drug Classes

• Antimetabolites
• Mitotic inhibitors
• Anti-tumor antibiotics
• Alkylating agents and platinum compounds
• Immunotherapy (e.g. cancer vaccine)
• Targeted Therapies
• Biologic agents (e.g. monoclonal antibodies)
• Small molecule inhibitors (e.g. protein kinase inhibitors)
• Antisense compounds (e.g. antisense DNA)